Literature DB >> 18988606

European Union. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population.

.   

Abstract

This document has been developed by the ad hoc group for the development of implementing guidelines for Directive 2001/20/EC relating to good clinical practice in the conduct of clinical trials on medicinal products for human use, chaired by the European Commission. The document provides recommendations on various ethical aspects of clinical trials performed in children from birth up to the legal age of adulthood. This will contribute to the protection of all children who are the subject of clinical trials. As the approval of clinical trials, including ethical approval, is performed by the Member States, any recommendations on ethical aspects of clinical trials in children will also facilitate a harmonised approach to the application of the clinical trials directive across the EU, thereby facilitating the conduct of clinical trials in the EU and in whichever country the paediatric trial occurs. The protection against the risks of research in such a vulnerable population is paramount whilst this should not lead to denying them the benefits of research. Children are not small adults and there is a need to carry out specific trials that cannot be performed in adults. In general, children (minors) are unable to consent (in the legal sense) but their assent should be sought using age appropriate information. Ethics Committees need paediatric expertise to balance the benefits and risks of research in children. The lack of legal ability to consent has implications on the design, analysis and the choice of comparators used in trials, which should only be performed by trained investigators with paediatric experience. Pain, fear, distress and parental separation should be prevented and minimised when unavoidable. The neonate represents the most vulnerable of all paediatric age groups and requires even more careful review. Finally, various other aspects relating to the performance of trials in children are discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18988606     DOI: 10.1163/157180908x333228

Source DB:  PubMed          Journal:  Eur J Health Law        ISSN: 0929-0273


  20 in total

1.  Ethical challenges in paediatric clinical trials in multiple sclerosis.

Authors:  Silvia N Tenembaum
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

Review 2.  Management and return of incidental genomic findings in clinical trials.

Authors:  C Ayuso; J M Millan; R Dal-Re
Journal:  Pharmacogenomics J       Date:  2014-10-28       Impact factor: 3.550

3.  Setting risk thresholds in biomedical research: lessons from the debate about minimal risk.

Authors:  Annette Rid
Journal:  Monash Bioeth Rev       Date:  2014 Mar-Jun

4.  Challenges in conducting clinical trials in children: approaches for improving performance.

Authors:  Steven E Kern
Journal:  Expert Rev Clin Pharmacol       Date:  2009-11-01       Impact factor: 5.045

Review 5.  Ethics review of pediatric multi-center drug trials.

Authors:  Allison C Needham; Mufiza Z Kapadia; Martin Offringa
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

6.  Effect of topical anaesthetics on interstitial colloid osmotic pressure in human subcutaneous tissue sampled by wick technique.

Authors:  Hans Jørgen Timm Guthe; Torbjørn Nedrebø; Olav Tenstad; Helge Wiig; Ansgar Berg
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

Review 7.  Aspects of vulnerable patients and informed consent in clinical trials.

Authors:  Maria Kuthning; Ferdinand Hundt
Journal:  Ger Med Sci       Date:  2013-01-21

8.  Observational research with adolescents: a framework for the management of the parental permission.

Authors:  Miguel Ruiz-Canela; Cristina Lopez-del Burgo; Silvia Carlos; Maria Calatrava; Carlos Beltramo; Alfonso Osorio; Jokin de Irala
Journal:  BMC Med Ethics       Date:  2013-01-03       Impact factor: 2.652

9.  Recommendations and evidence for reporting items in pediatric clinical trial protocols and reports: two systematic reviews.

Authors:  April V P Clyburne-Sherin; Pravheen Thurairajah; Mufiza Z Kapadia; Margaret Sampson; Winnie W Y Chan; Martin Offringa
Journal:  Trials       Date:  2015-09-18       Impact factor: 2.279

10.  Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.

Authors:  Miguel W Tregnaghi; Xavier Sáez-Llorens; Pio López; Hector Abate; Enrique Smith; Adriana Pósleman; Arlene Calvo; Digna Wong; Carlos Cortes-Barbosa; Ana Ceballos; Marcelo Tregnaghi; Alexandra Sierra; Mirna Rodriguez; Marisol Troitiño; Carlos Carabajal; Andrea Falaschi; Ana Leandro; Maria Mercedes Castrejón; Alejandro Lepetic; Patricia Lommel; William P Hausdorff; Dorota Borys; Javier Ruiz Guiñazú; Eduardo Ortega-Barría; Juan P Yarzábal; Lode Schuerman
Journal:  PLoS Med       Date:  2014-06-03       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.